Kyle R Duchman1, Yubo Gao2, Benjamin J Miller1. 1. Department of Orthopaedics and Rehabilitation, University of Iowa, 200 Hawkins Drive, 01015 JPP, Iowa City, IA 52242, USA. Electronic address: kyle-duchman@uiowa.edu. 2. Department of Orthopaedics and Rehabilitation, University of Iowa, 200 Hawkins Drive, 01015 JPP, Iowa City, IA 52242, USA. Electronic address: yubo-gao@uiowa.edu.
Abstract
BACKGROUND: The current study aims to determine cause-specific survival in patients with Ewing's sarcoma while reporting clinical risk factors for survival. METHODS: The Surveillance, Epidemiology, and End Results (SEER) Program database was used to identify patients with osseous Ewing's sarcoma from 1991 to 2010. Patient, tumor, and socioeconomic variables were analyzed to determine prognostic factors for survival. RESULTS: There were 1163 patients with Ewing's sarcoma identified in the SEER Program database. The 10-year cause-specific survival for patients with non-metastatic disease at diagnosis was 66.8% and 28.1% for patients with metastatic disease. Black patients demonstrated reduced survival at 10 years with an increased frequency of metastatic disease at diagnosis as compared to patients of other race, while Hispanic patients more frequently presented with tumor size>10cm. Univariate analysis revealed that metastatic disease at presentation, tumor size>10cm, axial tumor location, patient age≥20 years, black race, and male sex were associated with decreased cause-specific survival at 10 years. Metastatic disease at presentation, axial tumor location, tumor size>10cm, and age≥20 years remained significant in the multivariate analysis. CONCLUSIONS: Patients with Ewing's sarcoma have decreased cause-specific survival at 10 years when metastatic at presentation, axial tumor location, tumor size>10cm, and patient age≥20 years.
BACKGROUND: The current study aims to determine cause-specific survival in patients with Ewing's sarcoma while reporting clinical risk factors for survival. METHODS: The Surveillance, Epidemiology, and End Results (SEER) Program database was used to identify patients with osseous Ewing's sarcoma from 1991 to 2010. Patient, tumor, and socioeconomic variables were analyzed to determine prognostic factors for survival. RESULTS: There were 1163 patients with Ewing's sarcoma identified in the SEER Program database. The 10-year cause-specific survival for patients with non-metastatic disease at diagnosis was 66.8% and 28.1% for patients with metastatic disease. Black patients demonstrated reduced survival at 10 years with an increased frequency of metastatic disease at diagnosis as compared to patients of other race, while Hispanic patients more frequently presented with tumor size>10cm. Univariate analysis revealed that metastatic disease at presentation, tumor size>10cm, axial tumor location, patient age≥20 years, black race, and male sex were associated with decreased cause-specific survival at 10 years. Metastatic disease at presentation, axial tumor location, tumor size>10cm, and age≥20 years remained significant in the multivariate analysis. CONCLUSIONS:Patients with Ewing's sarcoma have decreased cause-specific survival at 10 years when metastatic at presentation, axial tumor location, tumor size>10cm, and patient age≥20 years.
Authors: Dagmar Adamkova Krakorova; Katerina Kubackova; Ladislav Dusek; Tomas Tomas; Pavel Janicek; Stepan Tucek; Jana Prausova; Igor Kiss; Iva Zambo Journal: Pathol Oncol Res Date: 2017-08-12 Impact factor: 3.201
Authors: Hamdan Ahmed Pasha; Shayan Khalid Ghaloo; Muhammad Wasif; Moghira Iqbaluddin Siddiqui; Nasir Ud Din Journal: Turk Arch Otorhinolaryngol Date: 2020-03-26
Authors: Azeem Tariq Malik; John H Alexander; Joel L Mayerson; Safdar N Khan; Thomas J Scharschmidt Journal: Clin Orthop Relat Res Date: 2020-10 Impact factor: 4.755